Table 4.

Sequential WOMAC A Scores – Pain

Group	Baseline	Week 1	Week 2	Week 4	Week 6	Week 8
Placebo	8.7 ± 1.0	8.9 ± 1.1	8.5 ± 1.2	8.4 ± 1.2	6.8 ± 1.1 *	6.3 ± 1.2 *
A	9.1 ± 1.2	8.1 ± 1.2 *	7.5 ± 1.2 **	6.5 ± 1.2 **	6.4 ± 1.2 **	6.3 ± 1.1 **
B	8.0 ± 1.1	7.5 ± 1.1	6.9 ± 1.1 **	5.7 ± 1.0 **	5.6 ± 1.1 **	5.0 ± 0.9 **
C	8.7 ± 1.0	8.0 ± 1.0b	6.9 ± 0.9 ***	5.6 ± 0.8 ***	5.0 ± 0.8 ***	4.3 ± 0.7 ***

Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 0.001.